PHARMACOKINETICS AND TISSUE DISTRIBUTION OF ANTIMONY (V) AFTER MULTIPLE INTRAMUSCULAR ADMINISTRATIONS IN THE HAMSTER
暂无分享,去创建一个
[1] Malcolm Rowland,et al. Physiologic modeling of cyclosporin kinetics in rat and man , 1991, Journal of Pharmacokinetics and Biopharmaceutics.
[2] Chris Clausen,et al. Lithium pharmacokinetics: Single-dose experiments and analysis using a physiological model , 1980, Journal of Pharmacokinetics and Biopharmaceutics.
[3] S. Croft,et al. Pharmacokinetics of Antimony in Patients Treated with Sodium Stibogluconate for Cutaneous Leishmaniasis , 2004, Pharmaceutical Research.
[4] A. Mullen,et al. Pharmacokinetics, Toxicities, and Efficacies of Sodium Stibogluconate Formulations after Intravenous Administration in Animals , 2003, Antimicrobial Agents and Chemotherapy.
[5] J. Ledoux. Features of the comparative pharmacokinetics of lithium; a potential application of its use in livestock farming. , 2003, Medical hypotheses.
[6] C. Jaffe,et al. Emergence of visceral leishmaniasis in central Israel. , 1998, The American journal of tropical medicine and hygiene.
[7] C. Riera,et al. Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum. , 1998, Veterinary parasitology.
[8] C. D. D. de Paula,et al. [The evaluation of the tolerance and nephrotoxicity of pentavalent antimony administered in a dose of 40 mg Sb V/kg/day, 12/12 hr, for 30 days in the mucocutaneous form of leishmaniasis]. , 1997, Revista da Sociedade Brasileira de Medicina Tropical.
[9] J. Berman. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] J. Valladares,et al. Disposition of antimony after the administration of N-methylglucamine antimoniate to dogs , 1996, Veterinary Record.
[11] S. Croft,et al. Skin uptake, distribution, and elimination of antimony following administration of sodium stibogluconate to patients with cutaneous leishmaniasis , 1995, Antimicrobial agents and chemotherapy.
[12] D. Podzamczer,et al. Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS. , 1990, The Journal of infection.
[13] R. Pearson,et al. Leishmania species: visceral (kala-azar), cutaneous, and mucosal leishmaniasis. , 1990 .
[14] J. Berman,et al. Pharmacokinetics of pentavalent antimony (Pentostam) in hamsters. , 1988, The American journal of tropical medicine and hygiene.
[15] J. Berman. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. , 1988, Reviews of infectious diseases.
[16] D. Smith,et al. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. , 1988, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[17] L. Gradoni,et al. Canine Leishmaniasis in the Mediterranean Area and Its Implications for Human Leishmaniasis , 1986 .
[18] P. Mormède,et al. Pharmacokinetics and tissue distribution of lithium in chicken (Gallus domesticus). , 1981, Comparative biochemistry and physiology. C: Comparative pharmacology.
[19] W. Hockmeyer,et al. RENAL CLEARANCE OF PENTAVALENT ANTIMONY (SODIUM STIBOGLUCONATE) , 1980, The Lancet.
[20] John E. Bennett,et al. Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .